WHAT IS KNOWN AND OBJECTIVE

More than 200 countries have been affected by COVID-19, and 3 110 369 confirmed patients and 226 294 deaths have been reported by the World Health Organization (WHO) as of 30 April 2020.1,2 The WHO interim guideline recommends symptomatic supportive care and administration of antiviral agents based on the severity of symptoms and risk factors.3 The Infectious Diseases Society of America (IDSA) has published guidelines on managing patients with COVID-19, but their recommendation is associated with limited clinical trials.4

Thus, investigational drugs have been prescribed for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).5 Lopinavir/ritonavir has been presented as an immediate oral (po) therapy for COVID-19. In Korea, lopinavir/ritonavir was the main medication administered during peak outbreaks before the global spread.6 However, a study by Cao et al7 challenges this result and cautions the use of this regimen because it lacks effectiveness. Consequently, hydroxychloroquine may be considered the preferred choice; however, its antiviral mechanisms have not been fully investigated and it has even been found to worsen viral infections in animal studies.8,9 Remdesivir has shown positive results in vitro and in some clinical studies, and other clinical trial results are still expected.10,11 Here, we describe common investigational medications we have used on our patients, focusing on the practice aspects such as criteria of use, dose adjustments, formulations, adverse reactions and drug interactions to support clinical decision; however, these suggestions should be applied with clinical discretion.
Hydroxychloroquine and chloroquine with zinc supplement

2.1.1 | Current evidence updates

Hydroxychloroquine and chloroquine are indicated for the prophylaxis and treatment of malaria.12,13 Hydroxychloroquine is also a synthetic disease-modifying anti-rheumatic drug used to treat rheumatoid arthritis without significant adverse effects.10 Both agents have demonstrated good in vitro activity against SARS-CoV-2 and reduce the duration of viral shedding.8,9 Synergistic viral load reduction was reported following co-treatment with hydroxychloroquine and azithromycin in patients with confirmed COVID-19 in early March of 2020.14,15 However, no human results have reported the synergism in COVID-19, capsules containing 25 mg and 50 mg zinc acetate are available.30 Zinc supplementation may be considered along with chloroquine and hydroxychloroquine based on long-standing research reports that chloroquine is a zinc ionophore and zinc inhibits the coronavirus in vitro.27,28 Recent clinical trials to evaluate the effects of supplementation with zinc and vitamin C on COVID-19 have also been planned.29 Although no standard method of zinc supplementation has been established in the treatment of COVID-19, capsules containing 25 mg and 50 mg zinc acetate are available.30

2.1.2 | Administration methods

Hydroxychloroquine

Several anecdotal dosing regimens have been used: (a) 400 mg daily for 5 days17,18; (b) 400 mg twice daily (bid) on day 1, followed by 400 mg daily for 5 days19; (c) 400 mg bid on day 1, followed by 200 mg bid for 4 days20,21; (d) 600 mg bid on day 1, followed by 400 mg bid for 6 days22; and (e) the US Food and Drug Administration (FDA) has recommended 800 mg on day 1, followed by 400 mg daily for 4-7 days for emergency use authorization (EUA).13 Published regimens with azithromycin are as follows: (f) 200 mg hydroxychloroquine three times a day (tid) for 10 days with 500 mg azithromycin daily on day 1, followed by 250 mg daily for 4 days14 and (g) 600 mg hydroxychloroquine daily for 10 days with 500 mg azithromycin daily on day 1, followed by 250 mg daily for 4 days.15 For patients who cannot swallow or have insufficient gastrointestinal functions, extemporaneous formulations of oral suspensions of 25 mg/mL hydroxychloroquine and 10 mg base/mL chloroquine are available as referenced.23-25 These formulations are stable when refrigerated for 30 days and should be shaken well before use. Hydroxychloroquine is extensively metabolized by the liver.26

Chloroquine

The usual chloroquine dosage for malaria treatment is 1000 mg orally, followed by 500 mg orally after 6-8 hours, and then 500 mg daily for 2 days.13 In current COVID-19 trials, the doses being tested are (a) chloroquine diphosphate 450 mg bid on day 1, followed by 450 mg daily for 4 days as a low-dose regimen and (b) 600 mg bid for 10 days as a high-dose regimen.12 In another trial with favipiravir, chloroquine was administered at (c) 500 mg bid on day 1, followed by 500 mg daily on day 2-3, and then 250 mg daily on day 4,16,31,32 In a THDMS-COVID19 trial, chloroquine (d) 500 or 1000 mg/day was included in study arms added to darunavir with oseltamivir, ritonavir and favipiravir.23 Under the US FDA EUA, the recommended dose is (e) 1000 mg chloroquine phosphate on day 1, followed by 500 mg daily for 4-7 days of the total treatment.23 Chloroquine is less potent than hydroxychloroquine in vitro, but it may be used because hydroxychloroquine is unavailable in some countries or the supply is insufficient.12 Patients with a glomerular filtration rate <10 mL/min need a 50% dose reduction of chloroquine phosphate.25 Each 200 mg of hydroxychloroquine sulphate is equivalent to 155 mg base, and 500 mg chloroquine phosphate is equivalent to 300 mg base.12,34

2.1.3 | Monitoring

The risk of arrhythmia at high cumulative doses necessitates caution in administering chloroquine because of its narrow therapeutic window, especially in patients with QTc >500 ms. Furthermore, the electrocardiogram (ECG) may need to be monitored daily in patients with a high risk of cardiovascular disease.

2.2 | Lopinavir/ritonavir

2.2.1 | Current evidence updates

Lopinavir/ritonavir was the main combination treatment used in Korea, and it significantly reduced the viral load.35 However, it became an alternative option when hydroxychloroquine was contraindicated.2 Furthermore, Cao et al7 recommended its administration within 10 days after symptom onset because of the possible benefits of shortening the intensive care unit stay of patients who are treated 12 days before the onset of symptoms. Despite the disappointing results of single use of lopinavir/ritonavir, coadministration with interferon-β1b is currently under evaluation in clinical trials.36

2.2.2 | Administration methods

Lopinavir/ritonavir 400/100 mg po bid, the dose for human immunodeficiency virus (HIV) treatment, has been investigated for the treatment of patients with COVID-19.7 Investigational lopinavir/ritonavir 400/100 mg bid with ribavirin was used for Middle East
respiratory syndrome (MERS), and lopinavir/ritonavir 10/2.5 mg/kg plus favipiravir bid is under investigation in a clinical trial. Thus, a 14-day treatment with these doses is being considered for patients with COVID-19. Patients who are unable to swallow tablets can take an oral solution that is commercially available as lopinavir/ritonavir 80/20 mg/mL. The solution contains ethanol and propylene glycol, and therefore, it is incompatible with polyurethane feeding tubes. Thus, it may be administered using silicone and polyvinyl chloride feeding tubes. Oral solutions should be refrigerated and used within 2 months when stored at room temperature.

2.2.3 Monitoring

Approximately 14% of the participants were dropped from the trial because of gastrointestinal adverse events (6.8%-19.5%). Migraine (6.3%), hepatic injury (1%-29%), severe cutaneous eruptions and QTc prolongation have also been reported. The potential for multiple drug interactions should be closely monitored because this agent potently inhibits cytochrome P450 (CYP) 3A and P-glycoprotein (Table 1).

2.3 Remdesivir

2.3.1 Current evidence updates

In preclinical trials, remdesivir demonstrated significant activity against the SARS-CoV-2 and a high genetic barrier to resistance. The manufacturer of remdesivir restricts its supply through the 'expanded access' programme for experimental COVID-19 treatments and 'compassionate use' for pregnant women and children. This agent has shown promising results in vitro and the compassionate use trials showed a generally acceptable efficacy and safety, but the protocol did not include a comparison group administered the standard of care at participating institutions. Obtaining approval for this indication is highly anticipated based on the positive outcomes with patient in the trials; however, this agent would have very restricted use mainly for the most severely ill patients, as the ongoing trials have many exclusion criteria.

2.3.2 Administration methods

Remdesivir was tested at a dosage of 200 mg intravenously once on day 1, followed by 100 mg daily for 5-10 days or until respiratory symptoms improve. The lyophilized solid containing 100 mg preservative-free remdesivir needs to be reconstituted with sterile water for injection and diluted with intravenous infusion fluids to a concentration of 100 mg/20 mL remdesivir. No special training or equipment is required for drug administration.

2.3.3 Monitoring

One case of cardiac arrest and hypotension was reported during the trial (n = 673) in patients with Ebola viral infection. Nausea, vomiting, gastroparesis and haematochezia with increased liver enzyme levels were reported by three patients during its compassionate use to treat COVID-19. If possible, daily monitoring of renal and liver functions should be performed.

2.4 Tocilizumab

2.4.1 Current evidence updates

A retrospective, observational study (n = 21) administered 400 mg tocilizumab, an interleukin (IL)-6 blocker, intravenously once to patients who had respiratory failure, shock or organ failure. Although three patients received a subsequent dose, the benefit is unknown. However, the potential benefit in decreasing mortality was evident as no deaths were reported out of 21 patients.

2.4.2 Administration methods

Other dosages used in trials are 8 mg/kg (maximum, 800 mg/dose) intravenously every 12 hours (q12h) or one 200 mg intravenous dose (up to two doses). Subcutaneous tocilizumab at two 162 mg doses followed by two more doses after 12 hours has been used in combination with hydroxychloroquine (400 mg q12h followed by 200 mg q12h orally for total of 7 days) and azithromycin (500 mg daily orally for 3 days). It is stable at room temperature for 24 hours protected from light.

2.4.3 Monitoring

All patients should be monitored for signs and symptoms of infection before, during, and after treatment. Cases of severe liver damage and intestinal perforation have been reported. Although beneficial outcomes were observed in most patients, this should be interpreted cautiously as all patients in the study received routine treatment for 1 week and then tocilizumab was administered as an additional agent. The risk of neutropenia should be monitored.

2.5 Other medications

2.5.1 Ciclesonide

Ciclesonide is an inhaled corticosteroid for the treatment of asthma, which has been a potential candidate for repurposing in the treatment of patients with MERS or COVID-19. The dosage used in a current trial was 320 mcg q12h for 14 days.
systemic corticosteroids are contraindicated in severe pneumonia caused by viruses such as MERS-CoV and SARS-CoV because they suppress the innate immune system, resulting in increased viral replication. This recommendation is the same as that of the IDSA COVID-19 guidelines except for acute respiratory distress syndrome. There are claims of decreased immunosuppressive effects of this agent with presumably fewer systematic effects because of the administration route. The need for compliance to the recommended administration technique for this medication should be emphasized, if it becomes available for use based on trial results.

2.5.2 | Niclosamide

Another medication undergoing repurposing investigations for SARS-CoV-2 is niclosamide, an oral anthelmintic drug used worldwide at a single dose of 2 g/d. Niclosamide exerts anti-MERS activity, inhibits SARS-CoV replication and abolishes viral antigen synthesis in vitro, and therefore, is considered a possible treatment option. However, it is cytotoxic and has low absorption including low oral bioavailability (10%) and although efforts have been made to formulate derivatives to overcome these obstacles, its extensive clinical development as an antiviral agent may still be hindered. 

**Table 1** Examples of Lopinavir/ritonavir’s Drug Interactions

| Lopinavir (A)/ritonavir (B) | Avoid combination (X) | Need therapy change or monitoring (X) |
|-----------------------------|-----------------------|--------------------------------------|
| Increased the serum concentration of 'X' | | |
| 'A/B' (strong CYP3A4 inhibitor) may increase the serum concentration of 'X' | Ado-trastuzumab emtansine, avanafil, ticagrelor, budesonide(systemic), dasatinib, delamanid, domperidone, dronedarone, everolimus, lovastatin, lercanidipine, salmeterol, tamsulosin, terfenadine | amiodpine, aripiprazole, budesonide (oral, nasal, topical), clozapine, corticosteroids, CYP3A4 substrates, evoglipitin, fentanyl, imatinib, lacosamide, mirtazapine, oxycodone, pranlukast, thiopeta, trazodone |
| 'A/B' (strong CYP3A4 and P-glycoprotein inhibitor) may increase the serum concentration of 'X' | rivaroxaban | apixaban |
| 'A/B' (P-glycoprotein/ABCB1 inhibitor) may increase the serum concentration of 'X' | pazopanib, topotecan | afatinib, betrixaban, celiprolol, colchicine, doxorubicine, edoxaban, rifaximin, venetoclax |
| 'A/B' (protease inhibitors) may increase the serum concentration of 'X' or decrease the metabolism of 'X' | alfuzocin, midazolam, lovastatin, simprevir, simvastatin | atorvastatin, rosuvastatin, sildenafil, TCAs, CCBs, tacrolimus(topical) |
| 'A/B' (protease inhibitor) may enhance the adverse/toxic effects of 'X' | amiodarone, quinidine | methadone |
| 'A' may enhance the QTc-prolonging effect of 'X' | antihepaciviral combination products, voxilaprevir | rifabutine, bedaquiline, elvitegravir, ivermectin, vincristine, vinblastine |
| 'A' may increase the serum concentration of 'X' | amiodarone, metronidazole, flecainide, glecaprevir/pibrentasvir, propafenone | cyclosporin, digoxin, itraconazole, ketoconazole, linagliptin, prednisolone, quetiapine, taladafil, zolpidem |
| 'B' may increase the serum concentration of 'X' or may enhance the adverse effects | | |
| Decreased the serum concentration of 'X' | | |
| 'A/B' (protease inhibitors) may decrease the serum concentration of 'X' | darunavir, quinine, voriconazole | abacavir, estrogen derivatives, valproate products, tacrolimus, zidovudine |
| 'A' may decrease the serum concentration of 'X' | quinine, voriconazole | didanosine, progestines, warfarin |
| 'B' may decrease the serum concentration of 'X' | quinine, voriconazole | canagliflozin, deferoxamine, methadone, olanzapine, theophylline derivatives, warfarin, clopidogrel, thyroid products |
| Increased the serum concentration of 'A/B' | | |
| 'X' may increase the serum concentration of 'A' | clarithromycin | ketoconazole |
| 'X' may enhance the QTc-prolonging effect of 'A' | | |
| Decreased the serum concentration of 'A/B' | | |
| 'X' may decrease the serum concentration of 'A/B' (CYP3A4 Substrate) | fosamprevir | orlistat, sarilumab, siltuximab, tocilizumab |
| 'X' may decrease the serum concentration of 'A' | fosphenytoin, phenytoin, nelfinavir, carbamazepine, efavirenz, phenobarbital |

Abbreviations: CCB, calcium channel blocker; CYP3A4, cytochrome P450 3A4; QTc, corrected QT Interval; TCA, tricyclic antidepressants.
interventional trial has been registered to evaluate the use of chloroquine with or without azithromycin, favipiravir, nitazoxanide or ivermectin for the treatment of patients with COVID-19 in a real-life setting, but recruitment has not commenced as of 14 April 2020. 53

2.5.3 | High-dose intravenous immunoglobulin (IVIG)

The co-administration of high-dose intravenous immunoglobulin (IVIG) at 25 g/d for 5 days (body weight, 66 kg) with moxifloxacin was reported in a case series study. 54 Although no trials are currently recruiting, the IVIG doses used in protocols are in the range of 0.2-0.5 g kg$^{-1}$ day$^{-1}$ and the use of this agent is expected to be limited to patients in severe or critical conditions. 55

Other medications that are currently undergoing clinical trials with the associated dosages are baricitinib (4 mg/d orally) in combination with lopinavir/ritonavir (250 mg orally bid) 56; favipiravir (1600 mg bid on day 1, followed by 600 mg bid from day 2-7) with tocilizumab; 57 arbidol (200mg orally three times), oseltamivir (75 mg orally bid) and lopinavir/ritonavir(500 mg orally bid); 58 and sarilumab (400 mg intravenously) with azithromycin and hydroxychloroquine. 59

3 | WHAT IS NEW AND CONCLUSION

The National Medical Center in Korea has played a pivotal role in managing infectious diseases since the MERS outbreak in 2015 and now serves as the headquarters for COVID-19 treatment operations. 60 At the beginning of the current outbreak of COVID-19 in January 2020, the guidelines we adopted for treating patients infected with SARS-CoV-2 were established based on the previous experience with the MERS outbreak, although clinical outcomes still need to be evaluated. 61 We hope that this paper will help clinicians understand, prioritize and monitor the drugs being used until results of clinical trials are available.

ACKNOWLEDGEMENTS

We thank all the pharmacists, clinicians and other healthcare professionals who are actively fighting against COVID-19.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

AUTHOR CONTRIBUTIONS

SJR designed, conceptualized and wrote the original draft, and reviewed and supervised the paper; J EK designed, wrote the original draft and edited and reviewed the paper; SJR was responsible for funding acquisition.

FUNDING INFORMATION

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea Government Ministry of Science and ICT (MSIT) (2020R1A2C1009224) and the Ministry of Education (2017R1D1A1B03033389).

ORCID

Ji Eun Kang https://orcid.org/0000-0002-0642-2330

Sandy Jeong Rhie https://orcid.org/0000-0003-2554-3370

REFERENCES

1. World Health Organization. Coronavirus disease 2019 (COVID-19) situation report 74. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200403-sitrep-74-covid-19-mp.pdf?sfvrsn=4e043d03_4. Accessed March 28, 2020.

2. McMichael T, Currie DW, Clark S, et al. Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington. N Engl J Med. 2020;382(21):2005-2011.

3. World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: Interim guidance V 1.2. https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf. Accessed March 23, 2020.

4. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19 infection. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/. Accessed April 13, 2020.

5. World Health Organization. International Clinical Trials Registry Platform (ICTRP). All COVID-19 trials from the ICTRP database. http://www.who.int/ictrp/en/. Accessed March 30, 2020.

6. The Korean Society of Infectious Disease. Treatment recommendation of COVID-19 for healthcare professionals. (Korean). http://www.ksid.or.kr/ rang_board/inc/download.php?code=notice3&num=4833. Accessed March 17, 2020.

7. Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020;382(19):1787-1799.

8. Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). Ophthalmology. 2016;123(6):1386-1394.

9. Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020.

10. Agostini ML, Andres EL, Sims AC, et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. MBio. 2018;9(2):1-15.

11. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-271.

12. Product information of chloroquine phosphate. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/006002s044lbl.pdf. Accessed April 1, 2020.

13. U.S. Food and Drug Administration (FDA). Hydroxychloroquine sulfate health care provider fact sheet, version date 3/28/2020. https://www.fda.gov/media/136537/download. Accessed April 1, 2020.

14. Gautret P, Lagier JC, Pet P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;105949.

15. Molina JM, Delaugerre C, Goff J, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Méd Mal Infect. 2020;50(4):384.
16. Roques P, Thiberville SD, Dupuis-Maguiraga L, et al. Paradoxical effect of chloroquine treatment in enhancing Chikungunya virus infection. Viruses. 2018;10(5):1-18.

17. Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. MedRxiv. 2020.

18. Chen J, Liu D, Liu L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ (Med Sci). 2020;49(2):215-219.

19. ClinicalTrials.gov. Chloroquine phosphate post exposure prophylaxis for coronavirus disease (COVID-19). https://clinicaltrials.gov/ct2/show/NCT04318444?term=COVID&cond=hydroxychloroquine&draw=4&rank=1. Accessed March 24, 2020.

20. ClinicalTrials.gov. Outcomes related to COVID-19 treated with hydroxychloroquine among in-patients with symptomatic disease (ORCHID). https://clinicaltrials.gov/ct2/show/NCT04322991?term=COVID&cond=hydroxychloroquine&draw=3&rank=13. Accessed April 3, 2020.

21. ClinicalTrials.gov. Hydroxychloroquine to prevent Covid19 pneumonia (ALBERTA HOPE-Covid19). https://clinicaltrials.gov/ct2/show/NCT04329611?term=covid&cond=hydroxychloroquine&draw=3&rank=8. Accessed April 1, 2020.

22. ClinicalTrials.gov. Effectiveness of hydroxychloroquine in Covid19 patients (Covid). https://clinicaltrials.gov/ct2/show/NCT04328272?term=covid&cond=hydroxychloroquine&draw=1&rank=5. Accessed March 31, 2020.

23. U.S. Food and Drug Administration (FDA). Chloroquine phosphate health care provider fact sheet, version date 3/28/2020 2. FDA; 2020. https://www.fda.gov/media/136535/download. Accessed April 1, 2020.

24. Micromedex® (electronic version). http://www.micromedexsolutions.com.ssl.access.ewha.ac.kr. Accessed March 29, 2020

25. Pesko LJ. Compounding: Hydroxychloroquine. Am Druggist. 1993;207:57.

26. Mirochnick M, Barnett E, Clarke DF, McNamara E, Cabral H. Stability of chloroquine in an extemporaneously prepared suspension stored at three temperatures. Pediatr Infect Dis J. 1994;13(9):827-828.

27. Xue J, Moyer A, Peng B, Wu J, Hannafon BN, Ding WQ. Chloroquine is a zinc ionophore. PLoS One. 2014;9(10):e109180.

28. te Velthuis AJ, van den Worm SH, Sims AC, Baric RS, Snijder EJ, van Hemert MJ. Zn2+ inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. PLoS Pathog. 2010;6(6):e1001176.

29. ClinicalTrials.gov. A study of quintuple therapy to treat COVID-19 infection (HAZDpaC). https://clinicaltrials.gov/ct2/show/NCT04334512?term=zinc&cond=COVID-19&draw=2&rank=3. Accessed April 14, 2020.

30. Product information of zinc acetate. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125276s114lbl.pdf. Accessed April 15, 2020.

31. ClinicalTrials.gov. Chloroquine diphosphate for the treatment of severe acute respiratory syndrome secondary to SARS-CoV2 (CloroCOVID19). https://clinicaltrials.gov/ct2/show/NCT04323527. Accessed March 25, 2020.

32. ClinicalTrials.gov. Clinical trial of favipiravir tablets combine with chloroquine phosphate in the treatment of novel coronavirus pneumonia. https://clinicaltrials.gov/ct2/show/NCT04319900. Accessed March 26, 2020.

33. ClinicalTrials.gov. Various combination of protease inhibitors, oseltamivir, favipiravir, and chloroquine for treatment of COVID19: a randomized control trial (THDMS-COVID19). https://clinicaltrials.gov/ct2/show/NCT04303299. Accessed March 17, 2020.

34. Lim HS, Im JS, Cho JY, et al. Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. Antimicrob Agents Chemother. 2009;53(4):1468-1475.

35. Srf.org. Recommandations d’experts portant sur la prise en charge en réanimation des patients en période d’épidémie à SARS-CoV2 (In French). https://www.srf.org/wp-content/uploads/2020/03/ RFE-COVID_V3_FINAL1.pdf. Accessed April 16, 2020.

36. ClinicalTrials.gov. Trial of treatments for COVID-19 in hospitalized adults (DisCoVeRY). https://clinicaltrials.gov/ct2/show/NCT04315948?term=lopinavir+interferon&cond=covid&draw=2&rank=4. Accessed April 15, 2020.

37. Arabi YM, Allothman A, Balkhy HH, et al. Treatment of middle east respiratory syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials. 2018;19(1):81.

38. Product information of KALETRA(R) oral capsules, oral solution. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021226s030lbl.pdf. Accessed April 15, 2020.

39. Zhao Y. Three drugs fairly effective on novel coronavirus at cellular level. China News Service. http://www.xinhuanet.com/english/sh/2020-01/30/c_138742163.htm. Accessed February 1, 2020.

40. Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382(10):929-936.

41. Grein J, Ohmagari N, Shih D, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020.

42. ClinicalTrials.gov. Study to evaluate the safety and antiviral activity of remdesivir (GS-5734™) in participants with moderate coronavirus disease (COVID-19) compared to standard of care. https://clinicaltrials.gov/ct2/show/NCT04292730?cond=Remdesivir&draw=2&rank=6. Accessed March 3, 2020.

43. COVID-19 Investigation Team: First 12 patients with coronavirus disease 2019 (COVID-19) in the United States. medRxiv 2020. https://www.medrxiv.org/content/10.1101/2020.03.09.20032896v1.full.pdf. Accessed March 13, 2020.

44. Mulangu S, Dodd LE, Davey Jr RT, et al. A randomized, controlled trial of Ebola virus disease therapeutics [published online ahead of print November 27, 2019]. N Engl J Med. 2019;381(24):2293-2303.

45. WHO R&D Blueprint – Ad-hoc expert consultation on clinical trials for ebola therapeutics. Appendix 4: summaries of evidence from selected experimental therapeutics. https://www.who.int/ebola/drc-2018/summaries-of-evidence-experimental-therapeutics.pdf?ua=1. Accessed November 13, 2020.

46. Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. ChinaXiv. http://www.chinaxiv.org/user/download.htm?id=30387&filetype=pdf. Accessed April 13, 2020.

47. ClinicalTrials.gov. Clinical trial of combined use of hydroxychloroquine, azithromycin, and tocilizumab for the treatment of COVID-19 (TOCOVID). https://clinicaltrials.gov/ct2/show/NCT04332094?term=tocilizumab&cond=COVID&draw=4&rank=4. Accessed April 15, 2020.

48. Product information of ACTEMRA(R). https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125276s114lbl.pdf. Accessed April 13, 2020.

49. Matsuyama S, Kawase M, Nao N, et al. The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15 [published online ahead of print March 12, 2020]. bioRxiv. doi: 10.1101/2020.03.11.987016.

50. ClinicalTrials.gov. A trial of ciclesonide in adults with mild COVID-19. https://clinicaltrials.gov/ct2/show/NCT04330586. Accessed April 15, 2020.

51. Wu CJ, Jan JT, Chen CM, et al. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob Agents Chemother. 2004;48(7):2693-2696.

52. Xu J, Shi PY, Li H, Zhou J. Broad spectrum antiviral agent niclosamide and its therapeutic potential. ACS Infect Dis. 2020;6(5):909-915.
53. ClinicalTrials.gov. A real-life experience on treatment of patients with COVID-19. https://clinicaltrials.gov/ct2/show/study/NCT04345419?term=nicosamide&draw=3&rank=13. Accessed April 15, 2020.

54. Cao W, Liu X, Bai T, et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease Open Forum. Infect Dis. 2019;2020;7(3):ofaa102.

55. ClinicalTrials.gov. The efficacy of intravenous immunoglobulin therapy for severe 2019-nCoV infected pneumonia. https://clinicaltrials.gov/ct2/show/NCT04261426?term=intravenous+immunoglobulin&cond=COVID&draw=2&rank=1. Accessed April 15, 2020.

56. ClinicalTrials.gov. Baricitinib therapy in COVID-19. https://www.clinicaltrials.gov/ct2/show/NCT04358614?cond=baricitinib%2C+covid&draw=2&rank=1. Accessed May 1, 2020.

57. ClinicalTrials.gov. Favipiravir combined with tocilizumab in the treatment of coronavirus disease 2019. Accessed May 1, 2020.

58. ClinicalTrials.gov. An open, prospective/retrospective, randomized controlled cohort study to compare the efficacy of three antiviral drugs (Abidol Hydrochloride, Oseltamivir and Lopinavir/Ritonavir) in the Treatment of 2019-nCoV Pneumonia. Accessed May 1, 2020.

59. ClinicalTrials.gov. Efficacy of sarilumab + azithromycin + hydroxychloroquine, and sarilumab Alone, for adult patients hospitalized with moderate to severe COVID-19: a multicenter open-label 1:1 randomized controlled trial. Accessed May 1, 2020.

60. Choi WS, Kang CI, Kim Y, et al. Clinical presentation and outcomes of middle east respiratory syndrome in the Republic of Korea. Infect Chemother. 2016;48(2):118-126.

61. Chong YP, Song JY, Seo YB, Choi JP, Shin HS. Antiviral treatment guidelines for Middle East respiratory syndrome. Infect Chemother. 2015;47(3):212-222.

How to cite this article: Kang JE, Rhie SJ. Practice considerations on the use of investigational anti-COVID-19 medications: Dosage, administration and monitoring. J Clin Pharm Ther. 2020;45:1199–1205. https://doi.org/10.1111/jcpt.13199